Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy.
Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Crit Rev Oncol Hematol. 2021 Apr;160:103307. doi: 10.1016/j.critrevonc.2021.103307. Epub 2021 Mar 19.
The interest in maintenance therapy for patients with advanced cancers has been rapidly growing. Maintenance therapy is a useful strategy that may strengthen results of induction therapy thus extending survival and preserving the quality of life (QoL) with less toxicity. Maintenance also represents a suitable setting to investigate novel agents. The value of maintenance therapy after first-line chemotherapy has been well established in several solid tumours, such as colorectal, lung, breast, and ovarian cancer in which it is largely adopted. To date, there is no established role for maintenance therapy following first-line chemotherapy for advanced gastric cancer (GC). This review summarizes the current knowledge regarding maintenance strategies in advanced GC exploring cytotoxic agents, biologic agents and immunotherapy. We also critically review new issues to optimize randomized clinical trials for maintenance therapies and suggest clinical consideration to guide a personalized approach in daily clinical practice for this setting.
人们对晚期癌症患者维持治疗的兴趣正在迅速增长。维持治疗是一种有用的策略，它可以加强诱导治疗的效果，从而延长生存期并保持生活质量（QoL），同时减少毒性。维持治疗也是研究新药物的合适环境。在几种实体肿瘤中，如结直肠癌、肺癌、乳腺癌和卵巢癌，一线化疗后的维持治疗已经得到了很好的确立，并且在这些肿瘤中得到了广泛应用。迄今为止，一线化疗后晚期胃癌（GC）的维持治疗尚没有明确的作用。本综述总结了晚期 GC 维持治疗的最新策略，探讨了细胞毒性药物、生物制剂和免疫治疗。我们还批判性地回顾了新的问题，以优化维持治疗的随机临床试验，并提出了临床注意事项，以指导这一领域的个体化治疗。
